文献速递哮喘

2型低哮喘的治疗选择

Treatment options in type-2 low asthma.
PubMed 文献 · Eur Respir J · 2021-01-21

本综述聚焦于重度哮喘门诊中占30-50%的非过敏性、非嗜酸性「2型低」哮喘患者,描述其异质性与临床特征,总结中性粒细胞气道炎症、细菌感染及IL-6通路等病理机制,并评述大环内酯类、支气管热成形术及生物制剂等现有治疗证据。

要点

  • 2型低哮喘占重度哮喘门诊患者的30-50%,对IgE或2型细胞因子靶向生物制剂不适用。
  • 中性粒细胞气道炎症常与吸烟、肥胖和职业暴露相关,可能由持续细菌感染和IL-6通路驱动。
  • 长期低剂量大环内酯类、支气管热成形术及生物制剂的证据需批判性评估,其他通路研究正在进行。

核心结论

  • 2型低哮喘是常见且重要的临床表型,常存在可识别和治疗的临床问题,是快速发展的领域,有开发新型靶向治疗的潜力。

研究设计与样本

  • 综述,总结2型低哮喘的异质性、临床特征、病理机制及现有治疗选择的证据基础。

主要发现

  • 2型低哮喘患者占重度哮喘门诊的30-50%,对靶向IgE或IL-4、IL-5、IL-13的单克隆抗体不适用。
  • 中性粒细胞气道炎症常与吸烟、肥胖和职业暴露相关,可能由持续细菌感染和IL-6通路激活驱动。
  • 综述聚焦重度哮喘而非难以控制的哮喘,评述气道细菌感染识别、长期低剂量大环内酯类、支气管热成形术及生物制剂证据。
  • 正在研究的其他通路包括肿瘤坏死因子、IL-17、消退素、载脂蛋白、I型干扰素、IL-6和肥大细胞。

临床怎么用

  • 对重度哮喘患者应识别2型低表型,避免不适当地使用靶向2型炎症的生物制剂。
  • 针对可治疗特质如细菌感染、吸烟、肥胖和职业暴露进行评估和干预。
  • 长期低剂量大环内酯类和支气管热成形术的应用需基于现有证据批判性决策。

局限性

  • 2型低哮喘的病理生物学机制尚不清楚。
  • 现有治疗选择的证据基础有待进一步研究,新型靶向治疗仍在探索中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Monoclonal antibodies targeting IgE or the type-2 cytokines interleukin (IL)-4, IL-5 and IL-13 are proving highly effective in reducing exacerbations and symptoms in people with severe allergic and eosinophilic asthma, respectively. However, these therapies are not appropriate for 30-50% of patients in severe asthma clinics who present with non-allergic, non-eosinophilic, "type-2 low" asthma. These patients constitute an important and common clinical asthma phenotype, driven by distinct, yet poorly understood pathobiological mechanisms. In this review we describe the heterogeneity and clinical characteristics of type-2 low asthma and summarise current knowledge on the underlying pathobiological mechanisms, which includes neutrophilic airway inflammation often associated with smoking, obesity and occupational exposures and may be driven by persistent bacterial infections and by activation of a recently described IL-6 pathway. We review the evidence base underlying existing treatment options for specific treatable traits that can be identified and addressed. We focus particularly on severe asthma as opposed to difficult-to-treat asthma, on emerging data on the identification of airway bacterial infection, on the increasing evidence base for the use of long-term low-dose macrolides, a critical appraisal of bronchial thermoplasty, and evidence for the use of biologics in type-2 low disease. Finally, we review ongoing research into other pathways including tumour necrosis factor, IL-17, resolvins, apolipoproteins, type I interferons, IL-6 and mast cells. We suggest that type-2 low disease frequently presents opportunities for identification and treatment of tractable clinical problems; it is currently a rapidly evolving field with potential for the development of novel targeted therapeutics.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Hinks TSC, Levine SJ, Brusselle GG, et al. Treatment options in type-2 low asthma. Eur Respir J. 2021. PMID: 32586877. doi:10.1183/13993003.00528-2020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。